The sBLA submission in the US is based on positive Phase III trial of Ultomiris in gMG, which were announced by AstraZeneca's Rare Disease group, Alexion, in July 2021.

(RTTNews) - Dutch immunology company argenx SE (ARGX) announced Tuesday positive topline data from the Phase 3 ADAPT-SC study evaluating subcutaneous (SC) efgartigimod (1000mg efgartigimod-PH20 ...